k8凯发(中国)天生赢家·一触即发

News Center
Share the latest news with you
IMPACT Announces Acceptance of Two Abstracts of Senaparib for Presentation at the 2022 American Association for Cancer Research (AACR) Annual Meeting
2022-04-15

IMPACT Therapeutics announced that the results of PARP inhibitor Senaparib as a single agent and in combination with temozolomide (TMZ) for the treatment of advanced solid tumors will be presented in two posters at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2022 to be held April 8-13, 2022 (US Eastern time).

 

Details of the poster presentations

Title: Discovery and Development of PARP Inhibitor Senaparib

Author: Dr. Cai, et. al.

Date: Monday, April 11, 2022, 9:00 AM - 12:30 PM ET

Abstract ID: 1399

 

Summary of Results

Using pharmacophore models and the scaffold hopping technique, Impact discovered a highly potent and selective PARP inhibitor Senaparib. Preclinical data indicated that Senaparib has a wider therapeutic window compared to other marketed PARP inhibitors,and phase I clinical studies also confirmed that Senaparib has a wide therapeutic window. Senaparib is currently in several phase II and phase III clinical studies, including a pivotal phase III study as maintenance therapy in advanced ovarian cancer patients following first-line chemotherapy (Study FLAMES, NCT04169997), and Phase Ib/II clinical studies in combination with TMZ in advanced solid tumors and small cell lung cancer (SCLC) (NCT04434482) (see Abstract ID 1051-AACR2022).

 

Title: Combination of Senaparib with Temozolomide for the Treatment of Cancer

Author: Dr. Cai, et. al.

Date: Monday, April 11, 2022, 9:00 AM - 12:30 PM ET

Abstract ID: 1051

 

Summary of Results

Senaparib is a potent PARP inhibitor with good PARP trapping activity, and a wide therapeutic window both in pre-clinical and clinical studies (see Abstract ID 1399 ‐ AACR 2022). In vitro and in vivo combination studies of Senaparib with TMZ were conducted, with the goal of producing maximal antitumor efficacy with minimal toxicity. It was found that continuous daily dosing of combination of Senaparib with low dose TMZ showed synergistic effect and good tolerability in both CDX SCLC and PDX OC models. Accordingly, Phase Ib/II clinical studies of combination of Senaparib with low dose TMZ in patients with advanced solid tumors and SCLC were initiated (NCT04434482). Dose escalation has been completed, with excellent safety and encouraging clinical efficacy including durable (>1 year) PR and SD in several advanced solid tumor patients observed; RP2D has been determined and subsequent dose expansion study in SCLC is ongoing, which will be presented in detail at ASCO 2022.

 

 

News Recommendation
网站首页
k8凯发天生赢家·一触即发